Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000340325

Medchemexpress LLC Cediranib maleate | 857036-77-2 | 99.9% | 50 MG
SDP

Catalog No. 5000340325
Encompass_Preferred

Cediranib maleate is a highly potent, orally available VEGFR inhibitor. It effectively inhibits VEGF-stimulated proliferation and KDR phosphorylation in human umbilical vein endothelial cells and reduces vessel sprouting in coculture models. In vivo, it ablates experimental angiogenesis and inhibits the growth of various human tumor xenografts.

  • Highly potent, orally available VEGFR inhibitor
  • Inhibits VEGF-stimulated proliferation and KDR phosphorylation
  • Reduces vessel area, length, and branching at subnanomolar concentrations
  • Ablates experimental angiogenesis
  • Inhibits growth of established human tumor xenografts

Catalog No. 50-003-40325 Supplier Medchemexpress LLC Supplier No. HY1304950MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

Cediranib maleate is a highly potent, orally available VEGFR inhibitor. It effectively inhibits VEGF-stimulated proliferation and KDR phosphorylation in human umbilical vein endothelial cells and reduces vessel sprouting in coculture models. In vivo, it ablates experimental angiogenesis and inhibits the growth of various human tumor xenografts.

  • Highly potent, orally available VEGFR inhibitor
  • Inhibits VEGF-stimulated proliferation and KDR phosphorylation
  • Reduces vessel area, length, and branching at subnanomolar concentrations
  • Ablates experimental angiogenesis
  • Inhibits growth of established human tumor xenografts

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.